Merck Reports $1.3 Billion Net Loss in Q2 2026 Amid Increased R&D Expenses

Merck & Co., Inc. reported a net loss of $1.3 billion for the second quarter of 2026, a significant decline from a net income of $4.4 billion in the same period last year. This resulted in a basic loss per share of $0.54, compared to earnings of $1.76 per share in the prior year. For the first half of 2026, the company recorded a net loss of $5.6 billion, down from a net income of $9.5 billion in the first half of 2025. Total sales for the second quarter reached $16.6 billion, a 5% increase from $15.8 billion in the previous year, while year-to-date sales rose to $32.9 billion, up from $31.3 billion.

The financial downturn was largely attributed to substantial research and development expenses, which surged to $9.7 billion in the second quarter, compared to $4.0 billion in the same quarter of 2025. This increase was primarily due to charges related to the acquisitions of Cidara Therapeutics and Terns Pharmaceuticals, which totaled $14.7 billion in the first half of 2026. Additionally, costs associated with restructuring programs contributed to the overall financial strain, with restructuring costs amounting to $151 million in the second quarter.

In terms of strategic developments, Merck made significant acquisitions in 2026, including Cidara Therapeutics for $9.2 billion and Terns Pharmaceuticals for $6.8 billion. These acquisitions are expected to enhance Merck's product pipeline, particularly in oncology and infectious diseases. The company also launched Welireg in combination with Keytruda for certain cancer treatments, which has already shown promising sales growth. Furthermore, Merck's acquisition of TARGAN for $650 million aims to expand its Animal Health portfolio, particularly in poultry operations.

Operationally, Merck's sales growth was driven by its oncology franchise, particularly from Keytruda and Welireg, which saw increased demand. However, the company faced challenges in its diabetes and infectious disease segments, with sales of Januvia and Lagevrio declining significantly. The company reported a gross margin of 73.5% in the second quarter, down from 77.5% a year earlier, primarily due to higher costs associated with acquisitions and restructuring.

Looking ahead, Merck anticipates continued pressure on pricing and market access due to ongoing healthcare reforms and government pricing regulations. The company is also preparing for potential impacts from the expiration of exclusivity for several key products, including Januvia and Janumet. Despite these challenges, Merck remains focused on its strategic growth areas and expects to realize significant cost savings from its restructuring initiatives by the end of 2027.